Category - Developments

Developments

Helius Medical adds new PoNS clinic in Quebec City

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is opening a new PoNS clinic in Quebec City, Canada to be operated by Clinique Cortex. The PoNS device is authorized in Canada for the acute treatment of chronic...

September 13, 2019

Developments

Tocagen fails Phase 3 trial in recurrent brain cancer

Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with...

September 12, 2019

Developments

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...

September 12, 2019

Developments

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...

September 10, 2019

Developments

Zenabis to supply recreational cannabis to Ontario retail outlets

Zenabis Global (TSX:ZENA) inked a supply agreement with the Ontario Cannabis Retail Corp. (OCS) to supply adult-use recreational cannabis to retailers throughout the province. Zenabis will begin supplying OCS with 21...

September 10, 2019

Developments

Toronto Innovation Acceleration Partners in pact with Amgen

Toronto Innovation Acceleration Partners (TIAP), formerly MaRS Innovation, and Amgen (NASDAQ:AMGN) are collaborating to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member...

September 9, 2019

Developments

Soricimed, Image Analysis Group to validate SOR-C13 imaging markers

Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...

September 6, 2019

Developments

NEJM landmark cardiac study included genetic testing with Spartan Bioscience rapid genotyping system

The New England Journal of Medicine published results from a landmark clinical trial called, “Patient Outcome after Primary PCI” (POPular Genetics), that included genetic testing using the Spartan RX CYP2C19 rapid...

September 5, 2019

Developments

Precipio and U of Penn in joint pathology diagnostics collaboration

Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...

September 5, 2019

Developments

Versant Ventures launches medtech sector investment firm

Versant Ventures launched an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Vensana Capital debuted with the closing of its inaugural fund, Vensana Capital I, with...

September 5, 2019

Category - Developments

Subscribe